Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell Carcinoma

Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell Carcinoma

Kidney Cancer Conference Highlights from ASCO 2023Подробнее

Kidney Cancer Conference Highlights from ASCO 2023

Cabozantinib Plus Nivolumab for First-Line mRCCПодробнее

Cabozantinib Plus Nivolumab for First-Line mRCC

CheckMate 9ER update confirms benefits of nivolumab–cabozantinib in RCC | Cristina SuárezПодробнее

CheckMate 9ER update confirms benefits of nivolumab–cabozantinib in RCC | Cristina Suárez

COSMIC-021: Cabozantinib + atezolizumab gives clinical activity in inoperable metastatic UCПодробнее

COSMIC-021: Cabozantinib + atezolizumab gives clinical activity in inoperable metastatic UC

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCCПодробнее

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC

Molecular Targeted Therapies for Advanced HCCПодробнее

Molecular Targeted Therapies for Advanced HCC

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

Winship Grand Rounds July 19, 2017: Mehmet Asim Bilen, MDПодробнее

Winship Grand Rounds July 19, 2017: Mehmet Asim Bilen, MD

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinomaПодробнее

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma

Cab + atezo: a new treatment for naïve advanced ccRCCПодробнее

Cab + atezo: a new treatment for naïve advanced ccRCC